Today MagToday Mag
  • Home
  • World
  • Politics
  • Bussines
  • Tech
  • Science
  • Health
  • Sport
  • Style
  • More
    • Food
    • Travel
    • Real Estate
    • Crypto
    • Jobs
What's Hot

Vancouver’s Plan A Real Estate fined $10,000 for using ‘travel’ leases to duck law

May 21, 2022

A Conversation With Native Americans on Race | Op-Docs

May 21, 2022

Israel Confirms First Monkeypox Case | World News

May 21, 2022
Facebook Twitter Instagram
  • World
  • Bussines
  • Health
  • Real Estate
  • Style
  • Travel
  • Sport
Facebook Twitter Instagram
Today Mag Today Mag
  • Home
  • World
  • Politics
  • Bussines
  • Tech
  • Science
  • Health
  • Sport
  • Style
  • More
    • Food
    • Travel
    • Real Estate
    • Crypto
    • Jobs
Contact Us
Today MagToday Mag
Home»Science»FDA offers funding for biosimilar regulatory science pilot
Science

FDA offers funding for biosimilar regulatory science pilot

TodayMagBy TodayMagMarch 7, 2022No Comments3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


Posted 07 March 2022 | By Michael Mezher 

The US Food and Drug Administration’s (FDA) is offering funding for several research proposals under the regulatory science pilot for biosimilars under the upcoming Biosimilar User Fee Amendments (BsUFA III) program, with a $5 million funding opportunity announced on Monday.
 
The agency and industry agreed to fund the regulatory science pilot during the negotiations for the third iteration of the agency’s biosimilar review program. The five-year program, which will run from FY2023-2027, must still be approved by Congress. (RELATED: Regulatory science pilot floated in BsUFA III negotiations, Regulatory Focus 15 June 2021; BsUFA III commitment letter details FDA, industry goals for biosimilars program, Regulatory Focus 21 September 2021)
 
The broad goals of the regulatory science program are to advance the development of interchangeable products and to make biosimilar development more efficient. The agency only recently approved Mylan’s Semglee (insulin glargine-yfgn) as the first interchangeable biosimilar product. FDA says it will conduct research under the proposed BsUFA III Regulatory Science Pilot Program, develop “foundational guidance” and host a stakeholder workshop on the development of interchangeable products.
 
The newly announced funding opportunity calls for proposals, with up to five awards of $1-2 million possible. The agency notes that while it will review the proposals in advance of BsUFA’s passage, “All awards will be subject to funding and reauthorization of BsUFA.”
 
FDA said it hopes to “address a diversity of topics related to improving the efficiency of biosimilar products development and advancing the development of interchangeable biological products.” Some potential topical areas for projects include evaluating methodologies and standards to predict immunogenicity and looking at opportunities for streamlined and targeted biosimilar development.
 
The agency notes that proposals “must be applicable across more than one product or product class” and that the “resulting data must be of sufficient reliability, quality, and impact to support or be a critical milestone in changes in regulatory expectations.”
 
“A variety of project types are welcomed under this [funding opportunity announcement] FOA, including analytical methodology (including bioassay) development, in silico tools, real world evidence, pharmacology studies, ancillary studies in parallel to planned or ongoing clinical trials, and combinations of these project types,” FDA said.
 
The agency is “particularly interested in projects that efficiently and convincingly achieve intended objectives.” While novel methodologies and tools are welcomed, FDA said they must be validated or have a “feasible approach to validation” to be considered.
 
FDA is seeking applications through 9 May 2022, with accepted research projects beginning in September 2022 at the earliest. The agency said it will spend up to $5 million in FY2022 in support of the program and that it will grant up to five awards of $1 million per year.
 
FOA

 

© 2022 Regulatory Affairs Professionals Society.




Source link

biosimilar FDA funding Offers pilot Regulatory science
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
TodayMag
  • Website

Related Posts

The First Superhero to Gain Superpowers From a Science Accident

May 21, 2022

Undersea internet cables can detect earthquakes

May 19, 2022

A Playbook for Science Denial, ‘Scientific Phallocracy’ in the Animal Kingdom, and More

May 17, 2022

Why the Large Hadron Collider matters

May 15, 2022
Add A Comment

Leave A Reply Cancel Reply

Editors Picks

‘Sheer Tenacity’: Taiwan Skier Falls on Slope, Picks Self Up | World News

February 13, 2022

Brexit LIVE: Hannan picks out shadowy civil servants pulling rug from under Boris’ EU plan | Politics | News

January 23, 2022

What to wear this weekend: FEMAIL picks out the best ‘it’ dresses for effortless style this season

December 23, 2021

Good Weekend’s style picks of the week

December 17, 2021
Latest Posts

Subscribe to Updates

Get the latest sports news from SportsSite about soccer, football and tennis.

Your source for the serious news. This demo is crafted specifically to exhibit the use of the theme as a news site. Visit our main page for more demos.

We're social. Connect with us:

Facebook Twitter Instagram Pinterest YouTube
Categories
  • World
  • Bussines
  • Health
  • Real Estate
  • Style
  • Travel
  • Sport
Useful Links
  • Home
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms Of Services
  • Sitemap

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2022 TodayMag
  • Home
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms Of Services
  • Sitemap

Type above and press Enter to search. Press Esc to cancel.